VIR-576 (Active substance against HIV infection) - VIRO Pharmaceuticals GmbH & Co. KG
VIR-576 is the main product of VIRO Pharmaceuticals GmbH & Co. KG. The company was founded in 2005 and develops antiviral peptides. VIR-576 prevents the HIV virus from entering into the immune cells. After completion of the preclinical work, a clinical Phase I/II study is currently being performed with the aim of proving the effects of VIR-576 (reducing the viral load) and its safety and tolerability.
VIR-576 is the main product of VIRO Pharmaceuticals GmbH & Co. KG. The company was founded in 2005 and develops antiviral peptides. VIR-576 prevents the HIV virus from entering into the immune cells. After completion of the preclinical work, a clinical Phase I/II study is currently being performed with the aim of proving the effects of VIR-576 (reducing the viral load) and its safety and tolerability.
